Press release
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at the European Respiratory Society International Congress 2023. Dr. Roham Zamanian, Professor of Pulmonary and Critical Care Medicine at Stanford University, will present the data during a session on novel treatments in pulmonary hypertension management on Sunday, September 10th.\n\n\nThe TORREY FRI sub-study utilized novel, non-invasive CT imaging techniques from Fluidda, an innovative medical technology company, to evaluate the impact of seralutinib treatment on pulmonary arterial blood vessel volume distribution. Following 24 weeks of seralutinib treatment, a statistically significant improvement in the ratio of blood vessel volume of small to large pulmonary arteries was observed as compared to placebo, indicating that seralutinib improved pulmonary vascular abnormalities associated with PAH. This improvement correlated with important cardiopulmonary hemodynamic measurements.\n\n\nGossamer will again partner with Fluidda to evaluate FRI measurements in a sub-study of the Phase 3 PROSERA Study. If the results are confirmed in Phase 3, this non-invasive imaging modality could further support seralutinib’s anti-proliferative, anti-inflammatory, and anti-fibrotic reverse-remodeling mechanism of action.\n\n\nSession and Presentation Details\n\n\nSession Title: Novelties in pulmonary hypertension management (Clinical)\nDate and Time: Sunday, September 10 from 9:30-10:45 AM CEST\nAbstract Title: Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): results of the TORREY phase 2 imaging substudy\nPresenting Author: Roham Zamanian, MD\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.\n\n\nAbout Fluidd...